The ITC's Potential Role In Hatch-Waxman Litigation
Imagine a scenario where a branded pharmaceutical company holds U.S. patents claiming a process for making an active pharmaceutical ingredient, intermediates of the API, or the finished branded drug product. The...To view the full article, register now.
Already a subscriber? Click here to view full article